{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T04:20:46Z","timestamp":1745382046143,"version":"3.40.4"},"reference-count":31,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1055\/a-2453-8887","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:53:08Z","timestamp":1745365988000},"page":"555-561","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvante und neoadjuvante Therapie des Melanoms"],"prefix":"10.1055","volume":"150","author":[{"given":"Dirk","family":"Debus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin S.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1245\/s10434-018-6689-x","article-title":"Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"25","author":"JE Gershenwald","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"114327","DOI":"10.1016\/j.ejca.2024.114327","article-title":"Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 \/ KEYNOTE-054 trial","volume":"211","author":"AMM Eggermont","year":"2024","journal-title":"European Journal of Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III\/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238","volume":"29","author":"J Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"02","key":"ref4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2023.09.2223","article-title":"Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III\/IV melanoma: 7-y results from CheckMate 238","volume":"34","author":"PA Ascierto","year":"2023","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","article-title":"Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"383","author":"R Dummer","year":"2020","journal-title":"N Engl J Med"},{"issue":"18","key":"ref6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1056\/NEJMoa2404139","article-title":"Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma","volume":"391","author":"GV Long","year":"2024","journal-title":"N Engl J Med"},{"issue":"01","key":"ref7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"T Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment \u2013 Update 2024","volume":"215","author":"C Garbe","year":"2025","journal-title":"Eur J Cancer"},{"issue":"17","key":"ref9","doi-asserted-by":"publisher","first-page":"LBA9505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9505","article-title":"Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study","volume":"41","author":"JJ Luke","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.annonc.2024.08.1146","article-title":"Pembrolizumab (pembro) vs placebo as adjuvant therapy for high-risk stage II melanoma: Long-term follow-up, rechallenge, and crossover in KEYNOTE-716","volume":"35","author":"JJ Luke","year":"2024","journal-title":"Ann Oncol"},{"issue":"02","key":"ref11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.annonc.2024.08.1145","article-title":"Adjuvant nivolumab v placebo in stage IIB\/C melanoma: 3-year results from CheckMate 76K","volume":"35","author":"GV Long","year":"2024","journal-title":"Ann Oncol"},{"issue":"S 16","key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS96","article-title":"Detection phae II\/III trial: Circulating tumour DNA-guided therapy for stage II B\/C melanoma after surgical recection","volume":"40","author":"R Lee","year":"2022","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref13","doi-asserted-by":"publisher","first-page":"LBA9512","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512","article-title":"Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial","volume":"42","author":"JS Weber","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"ref14","doi-asserted-by":"publisher","first-page":"LBA9503","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA9503","article-title":"Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201\/KEYNOTE-942 trial","volume":"41","author":"A Khattak","year":"2023","journal-title":"J Clin Oncol"},{"issue":"02","key":"ref16","doi-asserted-by":"publisher","first-page":"S712","DOI":"10.1016\/annonc\/annonc1597","article-title":"Adjuvant treatment of patients with stage III melanoma: 4-year follow-up time of multicenter real-world study","volume":"35","author":"E Livingstone","year":"2024","journal-title":"Ann Oncol"},{"issue":"11","key":"ref17","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"CU Blank","year":"2018","journal-title":"Nat Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.004","article-title":"Neo-Adjuvant Immunotherapy Emerges as Best Medical Practice, and Will Be the New Standard of Care for Macroscopic Stage III Melanoma","volume":"182","author":"ACJ van Akkooi","year":"2023","journal-title":"Eur J Cancer"},{"issue":"02","key":"ref19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9.","article-title":"Neoadjuvant Plus Adjuvant Dabrafenib and Trametinib Versus Standard of Care in Patients With High-Risk, Surgically Resectable Melanoma: A Single-Centre, Open-Label, Randomised, Phase 2 Trial","volume":"19","author":"RN Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"07","key":"ref20","doi-asserted-by":"publisher","first-page":"e378","DOI":"10.1016\/S1470-2045(19)30332-8","article-title":"Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium","volume":"20","author":"RN Amaria","year":"2019","journal-title":"Lancet Oncol"},{"issue":"02","key":"ref21","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"AM Menzies","year":"2021","journal-title":"Nat Med"},{"issue":"05","key":"ref22","doi-asserted-by":"crossref","first-page":"v535","DOI":"10.1093\/annonc\/mdz255.003","article-title":"3-year relapse-free survival, overall survival and long-term toxicity of (neo)adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma (OpACIN trial)","volume":"30","author":"CU Blank","year":"2019","journal-title":"Ann Oncol"},{"issue":"05","key":"ref23","doi-asserted-by":"publisher","first-page":"v910","DOI":"10.1093\/annonc\/mdz394.072","article-title":"18-months relaps free survival (RSF) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (Ipi) + Nivolumab (Nivo) in stage III melanoma","volume":"30","author":"EA Rozeman","year":"2019","journal-title":"Ann Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"JM Versluis","year":"2023","journal-title":"Ann Oncol"},{"issue":"06","key":"ref25","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial","volume":"28","author":"ILM Reijers","year":"2022","journal-title":"Nat Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104193","article-title":"Preoperative Therapy in Melanoma: Evolving Perspectives in Clinical Trials","volume":"104193","author":"H Kakish","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"18","key":"ref27","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/nejmoa2402604","article-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","volume":"391","author":"CU Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"03","key":"ref28","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"AC Huang","year":"2019","journal-title":"Nat Med"},{"issue":"16","key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9503","article-title":"NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy","volume":"40","author":"GV Long","year":"2022","journal-title":"J Clin Oncol"},{"issue":"09","key":"ref30","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","volume":"388","author":"SP Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"ref31","doi-asserted-by":"publisher","first-page":"LBA9501","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9501","article-title":"Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and\/or nodal metastases","volume":"42","author":"A Hauschild","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivoluumab in resectable melanoma","volume":"611","author":"RN Amaria","year":"2022","journal-title":"Nature"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2453-8887.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T23:53:18Z","timestamp":1745365998000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2453-8887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":31,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,4,22]]},"published-print":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2453-8887","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]}}}